Anthony B.
- Country
- France
- Department
- Digestive Medecine
Research Overview
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
Data & Insights
Has run more than one trial at 307 of 464 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating moderately to severely active Crohn's disease and ulcerative colitis, with particular emphasis on innovative therapeutic approaches.
- Perianal Fistulizing Crohn's Disease
- Post-operative Crohn's Disease Management
- Ulcerative Colitis Treatment Optimization
Focus includes evaluation of novel therapeutic agents and treatment strategies for inflammatory bowel conditions.
Advanced Therapeutic Approaches
Expertise in investigating microbiota-based treatments and novel pharmaceutical interventions for gastrointestinal disorders.
- Fecal Microbiota Transplantation
- Biologic Therapy Assessment
- Targeted Immunotherapy
Specializes in evaluating emerging treatments for inflammatory bowel conditions resistant to conventional therapies.
Treatment Innovation
Focuses on precision medicine approaches in gastrointestinal disease management, including telemonitoring strategies and patient-centered care models.
- E-monitoring Systems
- Patient Education Programs
- Treatment Response Assessment
Investigates personalized therapeutic strategies and treatment optimization protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.